Abstract
Kidney transplant patients are subject to an increased risk of developing cancer due to immunosuppressive therapy. On the contrary, the incidence of neoplasm on renal graft is low. In the case of graft tumors, a balance must be made between maintaining the functionality of the graft and radical treatment of the tumor. In the case of small tumors, it is possible to perform a nephron-sparing surgery, which allows to treat cancer with low recurrence rates and maintenance of renal function. In this study, we evaluate the management of graft tumors in a single transplant center. We registered three cases of graft tumors per 633 transplantations in a 20-year period with a calculated incidence of 0.47%. In all cases, thanks to a regular follow-up, it was possible to diagnose the neoplasm at an early stage and treat it by a nephron-sparing technique. It was thus possible to ensure the healing from the tumor and preservation of the function of the kidney graft. We report, in fact, a good maintenance of kidney function and the absence of recurrence at a long follow-up.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability
The data that support the findings of this study are available on request from the corresponding author (AP). The data are not publicly available because the containing information that could compromise the privacy of research participants.
Code Availability
Not applicable.
References
Morath C, Muller M, Goldschmidt H, Schwenger V, Opelz G, Zeier M. Malignancy in renal transplantation. J Am Soc Nephrol. 2004;15:1582–8.
Rama I, Grinyo JM. Malignancy after renal transplantation: the role of immunosuppression. Nat Rev Nephrol. 2010;6:511–9.
Tillou X, Doerfler A, Collon S, Kleinclauss F, Patard JJ, Badet L, et al. De novo kidney graft tumors: results from a multicentric retrospective national study. Am J Transplant. 2012;12:3308–15.
Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341:1725–30.
Guleryuz K, Doerfler A, Codas R, Coffin G, Hubert J, Lechevallier E, et al. A national study of kidney graft tumor treatments:toward ablative therapy. Surgery. 2016;160:237–44.
Warren H, Olsburgh J. Management of renal carcinoma and other renal masses in kidney graft. Current Urology Reports. 2020;21:8.
Griffith JJ, Amin KA, Waingankar N, Lerner S, Delaney V, Ames S, et al. Solid renal masses in transplanted allograft kidneys: a closer look at the epidemiology and management. Am J Transplant. 2017;17:2775–81.
Deng FM, Melamed J. Histologic variants of renal cell carcinoma: does tumor type influence outcome? Urol Clin North Am. 2012;39(2):119–32.
Leon G, Szabla N, Boissier R, Gigante M, Caillet K, Verhoest G. Tillou X; Members of “Comité de Transplantation de l’Association Française d’Urologie” (CTAFU). Kidney graft urothelial carcinoma: results from a multicentric retrospective national study. Urology. 2020 Jan;135:101–5. https://doi.org/10.1016/j.urology.2019.09.015.
Apel H, Walschburger-Zorn K, Häberle L, Wach S, Engehausen DG, Wullich B. De novo malignancies in renal transplant recipients: experience at a single center with 1882 transplant patients over 39 yr. Clin Transplant. 2013;27:E30–6.
Chiang Y-J, Chu S-H, Liu K-L, Lai W-J, Wang H-H. Silent urothelial cancer detected by sonography after renal transplantation. Transplant Proc. 2006;38:2084–5.
Cox J, Colli JL. Urothelial cancers after renal transplantation. Int Urol Nephrol. 2011;43:681–6.
Favi E, Raison N, Ambrogi F, Delbue S, Clementi MC, Lamperti L, et al. Systematic review of ablative therapy for the treatment of renal allograft neoplasms. World J Clin Cases. 2019 Sep 6;7(17):2487–504.
Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Montes SFP, et al. European Association of Urology Guidelines on renal cell carcinoma: the 2019 update. Eur Urol. 2019;75(5):799–810.
Gervais DA, Giambarresi L, Lane BR, Campbell S, Davis BJ, Bass EB, et al. Renal mass and localized renal cancer: AUA guideline. J Urol. 2017;198(3):520–9.
Author information
Authors and Affiliations
Contributions
Panarese A collected the data, analyzed the data, and drafted the manuscript.
D’Anselmi F processed the experimental data.
Montali F, Binda B, and Lancione L provided critical feedback and helped shape the research.
Natili A collected the data.
Pisani F contributed to the design and implementation of the research
All authors discussed the results and commented on the manuscript.
Corresponding author
Ethics declarations
Ethics Approval
Not applicable because this is a retrospective study in which no experimentation was carried out.
Consent to Participate
Informed consent was obtained from all individual participants included in the study.
Consent for Publication
Informed consent was obtained from all individual participants included in the study.
Conflict of Interest
The authors declare no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Surgery
Rights and permissions
About this article
Cite this article
Panarese, A., Binda, B., Natili, A. et al. Long-term Survival After Nephron-Sparing Surgery for Kidney Allograft Tumors: Case Reports from a Single Transplant Center. SN Compr. Clin. Med. 3, 1062–1065 (2021). https://doi.org/10.1007/s42399-021-00816-4
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s42399-021-00816-4